Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... ... 30, 2015 , ... Park Systems , world-leader in ... into new classes of Nanoscale Graphene-based materials poised to revolutionize industries such as ... of the 21st Century' by the researchers who were awarded the 2010 Nobel ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... Netherlands, August 4, 2011 SynCo Bio Partners ... today announced that its aseptic filling facility is again fully ... product batches for its clients after the expansion of its ... Class A zone is an important milestone in SynCo,s strategy ...
... An examination of the world,s largest river basins ... in the blooms of plankton associated with cholera outbreaks. ... increased temperature in coastal water, suggesting that predicting global ... complicated than first thought, according to a new study ...
... Corporation (Nasdaq: DNDN ) today reported results for ... the quarter ended June 30, 2011 was $49.6 million ... 30, 2010.  This included a $1.9 million reserve for ... or other pricing discounts offered pursuant to mandatory federal ...
Cached Biology Technology:SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 3Dendreon Reports Second Quarter 2011 Financial Results 2Dendreon Reports Second Quarter 2011 Financial Results 3Dendreon Reports Second Quarter 2011 Financial Results 4Dendreon Reports Second Quarter 2011 Financial Results 5Dendreon Reports Second Quarter 2011 Financial Results 6Dendreon Reports Second Quarter 2011 Financial Results 7Dendreon Reports Second Quarter 2011 Financial Results 8
(Date:6/18/2015)... 18, 2015 This report analyzes the worldwide ... following Product Segments, which includes Immunoassay Analyzers and Reagents: ... Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. The report ... Canada , Japan , ... Latin America , and Rest of ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
(Date:6/15/2015)... DALLAS , June 16, 2015 ... Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), ... Worldwide Forecast to 2020" published by MarketsandMarkets, The Natural ... Billion at a CAGR of 18.4% for the forecast ... Tables and   46 F igures spread   ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... known as ovarian ,chocolate, cysts for the brown liquid ... recurrence is common, which can cause ongoing pain and ... a simple and effective remedy the oral contraceptive ... and Shelley Reilly from Auckland, New Zealand, highlight a ...
... that are helping fight a multi-front war on cancer may ... researchers said. Cancer and cardiovascular disease, both among top ... 90 inhibitors as a treatment could become additional common ground, ... "I think hsp90 inhibitors may be some of the ...
... the use of Chinese wolfberries to improve vision deficiencies that ... research assistant professor of human nutrition, is studying wolfberries and ... show that the fruit can lower the oxidative stress that ... "I would not say that wolfberries are a medicine, but ...
Cached Biology News:New cancer therapy may fight cardiovascular disease 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 3
... Fluoroskan Ascent is a ... flexibility for all kinds of ... research and for clinical applications. ... biology are all important application ...
... SpeedVac Concentrator, the SPD series takes the ... modern twist., The SPD121P SpeedVac comes equipped ... optimizing runs; preventing samples from freezing; and ... the end-users preset level., Standard features on ...
... desktop unit ideal for use in laboratories with ... speed set at 12 rpm , Temperature ... Bottle capacity of four 35 x 150mm bottles, ... bottles , Consistent, repeatable results achieved with ...
... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
Biology Products: